Article added to library!
x
Sign in
Reset password
or connect with
Facebook
By signing in you are agreeing to our
Terms Of Service and Privacy Policy
  • See more
  • '); var ntfc_preview = ''; $.post('/api/v1/get_notifications', function(r) { var ntfc_read_pending = 0; var ntfc_pending = 0; $.each(r.notifications.pending, function(index, ntfc_object) { ntfc_read_pending++; ntfc_pending++; if (ntfc_read_pending
    ' + ntfc_object.full_name +'' + ntfc_object.time + '
    ' + ntfc_object.description +'
    '; }) if (ntfc_read_pending
    ' + ntfc_object.full_name +'' + ntfc_object.time + '
    ' + ntfc_object.description +'
    '; }) $('.notification-block .dropdown-menu').html(ntfc_preview); $('.notification-block .dropdown-menu').append('
  • See more
  • '); if (ntfc_pending > 0) { $('.notification-count').text(ntfc_pending).show(); } else { $('.notification-count').hide(); } } else { $('.notification-block .dropdown-menu').html(ntfc_preview); $('.notification-block .dropdown-menu').append('
  • See more
  • '); if (ntfc_pending > 0) { $('.notification-count').text(ntfc_pending).show(); } else { $('.notification-count').hide(); } } if (ntfc_read_pending == 0) { $('.notification-block .dropdown-menu').html('
  • You don\'t have any notifications
  • See more
  • '); $('.notification-count').hide(); } data = {'nid' : '', 'ntid' : 1}; $.post('/api/v1/notification_action', data, function(r) { if (r.request == 'OK') { $('.notification-count').hide(); } }); }, "json"); }); $('.search-save-box').on({ click : function(e) { e.preventDefault(); var search_attr = $(this).attr('rel').split(','); var p = search_attr[1]; var tf = search_attr[0]; window.location = '/search?tf='+tf+'&jc='+jc+'&keywords='+$(this).html()+'&s='+$('#sort_order').val()+'&p='+p; } }, '.search-name'); $( "#keywords_main, #keywords_mobile" ).focus(function(e) { show_saved_searches(e, $(this)); }); $(window).resize(function () { if ($('.search-save-box').is(':visible')) { if ($('#keywords_main').is(':visible')) var left_search_save = $('#keywords_main').offset().left; if ($('#keywords_mobile').is(':visible')) var left_search_save = $('#keywords_mobile').offset().left; $('.search-save-box').css('left',left_search_save); } }); $('.search-save-box').on({ click : function(e) { e.preventDefault(); delete_saved_search($(this)); } }, '.search-name-close'); $('.search-save-box, #keywords_main, #keywords_mobile').click(function(e) { e.stopPropagation(); }); $(document).click(function(e) { $('.search-save-box').hide(); }); $( "#keywords_main, #keywords_mobile" ).autocomplete({ source: function( request, response ) { // data contains the JSON object textStatus contains the status: success, error, etc $.post('/api/v1/searches', {'key' : request.term}, function(data, textStatus) { response(data); }, "json") }, select: function (event, ui) { var reportname = ui.item.value; var thelinks = '/search?tf='+$('#time_frame').val()+'&jc='+jc+'&keywords='+reportname+'&s='+$('#sort_order').val()+'&p='+$('#people_cluster').val(); } }); $('.search-go').click(function(e) { e.preventDefault(); window.location = get_search_url(); }); $('.logout').click(function(e) { e.preventDefault(); }); $('.header_keywords, .home_page_keywords').on('keydown', function(e) { if (e.keyCode == 13) { window.location = get_search_url(); } $('.search-save-box').hide(); }); $('.seemore').click(function(e){ e.stopImmediatePropagation(); }); });
    Jul 22, 2015
    Current Biology : CB
    An aversion to harming others is a core component of human morality and is disturbed in antisocial behavior [1-4]. Deficient harm aversion may underlie instrumental and reactive aggression, which both feature in psychopathy [5]. Past work has highlighted monoaminergic influences on aggression [6-11], but a mechanistic account of how monoamines regulate antisocial motives remains elusive. We previously observed that most people show a greater aversion to inflicting pain on others than themselves [12]. Here, we investigated whether this hyperaltruistic disposition is susceptible to monoaminergic control. We observed dissociable effects of the serotonin reuptake inhibitor citalopram and the dopamine precursor levodopa on decisions to inflict pain on oneself and others for financial gain. Computational models of choice behavior showed that citalopram increased harm aversion for both self and others, while levodopa reduced hyperaltruism. The effects of citalopram were stronger than those of levodopa. Crucially, neither drug influenced the physical perception of pain or other components of choice such as motor impulsivity or loss aversion [13, 14], suggesting a direct and specific influence of serotonin and dopamine on the valuation of harm. We also found evidence for dose dependency of these effects. Finally, the drugs had dissociable effects on response times, with citalopram enhancing behavioral inhibition and levodopa reducing slowing related to being responsible for another's fate. These distinct roles of serotonin and dopamine in modulating moral behavior have implications for potential treatments of social dysfunction that is a common feature as well as a risk factor for many psychiatric disorders. Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.
      
    Add Public PDF
      
      
    Upload my PDF
      

    Downloading PDF to your library...

    ADD A TAG      64 chars max

      Make private

    APPLIED TAGS

    Uploading PDF...

    PDF uploading

    Delete tag:

    The link you entered does not seem to be valid

    Please make sure the link points to nature.com contains a valid shared_access_token